Evidence map›Paper›PMID 42826199›Full record

ArticleScience advances2026

Tumor cell-intrinsic stress states drive sensitivity to CAR T cell therapy in pancreatic cancer.

Julia Fröse, Evelyn Chen, Charles A Whittaker, Paul Leclerc, Sean Doherty, Adam Langenbucher, Jasmine Shao, Riley D Hellinger, Daniel Goulet, Tuomas Tammela and 2 more

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Update of
    2025
5 · Who and what money

Authors and funding

12 authors.

Julia FröseThe David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA.ORCID 0000-0002-8179-1777
Evelyn ChenThe David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA.ORCID 0000-0003-1102-6997
Charles A WhittakerThe David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA.ORCID 0000-0002-2400-0094
Paul LeclercThe David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA.ORCID 0009-0007-6392-6512
Sean DohertyThe David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA.ORCID 0009-0007-2096-8026
Adam LangenbucherThe David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA.
Jasmine ShaoThe David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA.ORCID 0009-0004-6831-9832
Riley D HellingerThe David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA.ORCID 0000-0001-6303-3641
Daniel GouletThe David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA.
Tuomas TammelaCancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-3675-6961
Francisco J Sánchez-RiveraThe David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA.ORCID 0000-0002-8466-8563
Michael T HemannThe David H. Koch Institute for Integrative Cancer Research, Cambridge, MA 02142, USA.ORCID 0000-0001-6776-2163

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Investigating hypoxia as a determinant of malignant fates in pancreas cancerR01CA290400 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Hemann, Tuomas Tammela · 2024 to 2026
$2.1M
NCI NIH HHS P30 CA014051NCI NIH HHS R01 CA290400
6 · The paper itself

Abstract

Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of hematologic cancers but has shown limited efficacy in solid tumors, including pancreatic ductal adenocarcinoma (PDAC). The cellular and molecular factors that influence CAR T cell therapy response remain largely unknown. By integrating modular in vivo CRISPR screens with single-cell genomics and immunocompetent orthotopic models of PDAC, we uncover oxidative and proteotoxic stress pathways as previously unknown modulators of CAR T cell therapy response. Disruption of stress regulatory genes, particularly

Indexed as

Carcinoma, Pancreatic DuctalImmunotherapy, AdoptivePancreatic NeoplasmsReceptors, Chimeric AntigenStress, PhysiologicalAnimalsCell Line, TumorHumansKelch-Like ECH-Associated Protein 1MiceNF-E2-Related Factor 2Xenograft Model Antitumor AssaysKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2Receptors, Chimeric Antigen

Identifiers

PMID42826199
PMCPMC13641470

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.